31 May 2026
13m
ASCO 2026: "The results that we presented from the RASolute 302 trial are unprecedented." - The CEO behind this year's pancreatic cancer breakthrough walks us through the full results and implications
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.